共 48 条
- [1] Blaschke F.(2006)Vascular effects of TZDs: new implications Vascul. Pharmacol. 45 3-18
- [2] Spanheimer R.(2005)Microvascular endothelial cells sustain preadipocyte viability under hypoxic conditions In Vitro Cell Dev. Biol. Anim. 41 160-164
- [3] Khan M.(2005)A nuclear receptor atlas: 3T3-L1 adipogenesis Mol. Endocrinol. 19 2437-2450
- [4] Law R. E.(2004)Determination of rosiglitazone in coated tablets by MEKC and HPLC methods J. Pharm. Biomed. Anal. 36 909-913
- [5] Frye C.(2004)Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease Hypertension 43 297-305
- [6] Wu X.(2003)PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int. J. Obes. Relat. Metab. Disord. 27 147-161
- [7] Patrick C.(2007)Temporal and spatial variations of lipid droplets during adipocyte division and differentiation J. Lipid Res. 48 9-18
- [8] Fu M.(2003)Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 1008-1017
- [9] Sun T.(2004)Adipogenesis: usefulness of in vitro and in vivo experimental models Anim. Sci. 82 905-915
- [10] Bookout A. L.(2005)Essential role of fibroblast growth factor signaling in preadipocyte differentiation J. Clin. Endocrinol. Metab. 90 1226-1232